Dystrogen Therapeutics
Chicago, US · Founded 2017 · Delaware corporation
Dystrogen Therapeutics develops chimeric cell therapies created by fusing donor and recipient bone marrow-derived stem cells to address the immune system's response to foreign tissues and donor organs. The company operates in the therapeutics and cell therapy field.
Founders & leadership
Dystrogen Therapeutics was founded in 2017 by Maria Siemionow and Paul Lewicki.
MS
Maria SiemionowFounder & Chief Scientific Officer
PL
Paul LewickiCo-Founder & Board Member
KS
Kris SiemionowCo-Founder & CEO
Reported raises · per SEC filings
Form D private placements$1.1M disclosed across 1 round · 2019
▶$1.1MraisedAug 2019 · 14 investors · Other Health CareRule 506(b)
▶$1.1MraisedAug 2019 · 14 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Kris SiemionowDirector
- Offering amount
- $5M
- Amount sold
- $1.1M
- Minimum investment
- $85
- First sale
- Aug 2019
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does Dystrogen Therapeutics do?
- Dystrogen Therapeutics develops chimeric cell therapies created by fusing donor and recipient bone marrow-derived stem cells to address the immune system's response to foreign tissues and donor organs. The company operates in the therapeutics and cell therapy field.
- Who founded Dystrogen Therapeutics?
- Dystrogen Therapeutics was founded by Maria Siemionow, Paul Lewicki in 2017.
- How much funding has Dystrogen Therapeutics raised?
- Dystrogen Therapeutics has disclosed $1.1M raised across 1 round.
- Where is Dystrogen Therapeutics headquartered?
- Dystrogen Therapeutics is headquartered in Chicago, US.